Acumen Pharmaceuticals, Inc. (ABOS) annual cash flow statement — 7-year operating, investing & financing history
| Cash from Operations | -105.55M | -115.54M | -86.22M | -43.06M | -35.15M | -17.96M | -7.45M | -6.82M |
| Operating CF Margin % | - | - | - | - | - | - | -518.8% | -401.77% |
| Operating CF Growth % | -57.24% | -34.01% | -100.2% | -22.5% | -95.72% | -141.09% | -9.27% | - |
| Net Income | -113.28M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Depreciation & Amortization | 833K | -751K | 178K | 184K | 169K | 4K | 0 | 0 |
| Stock-Based Compensation | 4.92M | 9.85M | 9.63M | 6.14M | 3.06M | 922K | 154K | 174K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.48M | 1.81M | -5.35M | -888K | 487K | 81.42M | -586K | 147K |
| Working Capital Changes | -3.5M | -5.12M | 11.65M | 3.87M | 3.99M | 298K | 307K | 768K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -79K | 200K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 545K | -5.09M | 4.27M | -261K | 552K | 557K | 308K | 110K |
| Cash from Investing | 91.44M | 133.93M | 48.03M | -171.67M | 39.19M | -104.12M | 0 | 0 |
| Capital Expenditures | -9K | -88K | -16K | -21K | -161K | -40K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 3K | -39.35K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 39.35K | 0 | 0 | 0 |
| Cash from Financing | 35.74M | -34K | 6.93M | 151.75M | 3.91M | 200.47M | 44.67M | 6.24M |
| Debt Issued (Net) | 0 | 0 | -739K | 30M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 147K | -34K | 7.9M | 121.9M | 3.79M | 198.59M | 44.67M | 6.23M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -73K | -41K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 35.6M | 0 | -230K | -151K | 115K | 1.88M | 0 | 7K |
| Net Change in Cash | 21.64M | 18.36M | -31.26M | -62.98M | 7.94M | 78.39M | 37.23M | -579K |
| Free Cash Flow | -105.55M | -115.63M | -86.23M | -43.09M | -35.31M | -18M | -7.45M | -6.82M |
| FCF Margin % | - | - | - | - | - | - | -518.8% | -401.77% |
| FCF Growth % | -2.92% | -34.09% | -100.14% | -22.01% | -96.18% | -141.62% | -9.27% | - |
| FCF per Share | -1.67 | -1.91 | -1.44 | -0.89 | -0.87 | -0.47 | -0.26 | -0.24 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.95x | 0.84x | 0.82x | 0.82x | 0.18x | 1.02x | 0.86x |
| Interest Paid | 740K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ABOS stock.
Acumen Pharmaceuticals, Inc. (ABOS) generated $-115.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Acumen Pharmaceuticals, Inc. (ABOS) reported negative free cash flow of $115.6M in 2025, indicating capital requirements exceeded cash from operations.
Acumen Pharmaceuticals, Inc. (ABOS) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Acumen Pharmaceuticals, Inc. (ABOS) spent $0.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.